Advertisement

Resected Pancreatic Cancer

  • G. R. Varadhachary
  • J. L. Abbruzzese

Keywords

Pancreatic Cancer Pancreatic Adenocarcinoma Advanced Pancreatic Cancer Survival Duration Chemoradiation Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wolff R, Abbruzzese J, Evans D (2003) Neoplasms of the exocrine pancreas. In: Bast RC Jr, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III, Gansler TS (eds) Cancer Medicine. American Cancer Society and BC Decker, pp 1585–1614Google Scholar
  2. 2.
    Sener SF, Fremgen A, Menck HR, Winchester DP (1999) Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189:1–7PubMedCrossRefGoogle Scholar
  3. 3.
    Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM, Christein JD, Doolas A, et al (1999) Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 65:618–623; discussion 623–614PubMedGoogle Scholar
  4. 4.
    Kedra B, Popiela T, Sierzega M, Precht A (2001) Prognostic factors of long-term survival after resective procedures for pancreatic cancer. Hepatogastroenterology 48:1762–1766PubMedGoogle Scholar
  5. 5.
    Wenger FA, Peter F, Zieren J, Steiert A, Jacobi CA, Muller JM (2000) Prognosis factors in carcinoma of the head of the pancreas. Dig Surg 17:29–35PubMedCrossRefGoogle Scholar
  6. 6.
    Lim JE, Chien MW, Earle CC (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237:74–85PubMedCrossRefGoogle Scholar
  7. 7.
    Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, et al (1995) Pancreaticoduodenectomy for cancer of the head of the pancreas in 201 patients. Ann Surg 221:721–731; discussion 731–723PubMedCrossRefGoogle Scholar
  8. 8.
    Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al (2000) Resected adenocarcinoma of the pancreas — 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567–579PubMedCrossRefGoogle Scholar
  9. 9.
    Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Mosella G (2000) Survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Chir Ital 52:263–270PubMedGoogle Scholar
  10. 10.
    Benassai G, Mastrorilli M, Quarto G, Cappiello A, Giani U, Forestieri P, et al (2000) Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol 73:212–218PubMedCrossRefGoogle Scholar
  11. 11.
    Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al (2001) Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234:758–768PubMedCrossRefGoogle Scholar
  12. 12.
    Takai S, Satoi S, Toyokawa H, Yanagimoto H, Sugimoto N, Tsuji K, et al (2003) Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas 26:243–249PubMedCrossRefGoogle Scholar
  13. 13.
    Gunderson LL WC (1997) Pancreas and hepatobiliary tract. In: Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK (eds) Principles and Practice of Radiation Oncology. Lippincott-Raven Philadelphia, pp 1467–1488Google Scholar
  14. 14.
    Morganti AG, Valentini V, Macchia G, Alfieri S, Trodella L, Brizi MG, et al (2002) Adjuvant radiotherapy in resectable pancreatic carcinoma. Eur J Surg Oncol 28:523–530PubMedCrossRefGoogle Scholar
  15. 15.
    Kokubo M, Nishimura Y, Shibamoto Y, Sasai K, Kanamori S, Hosotani R, et al (2000) Analysis of the clinical benefit of intraoperative radiotherapy in patients undergoing macroscopically curative resection for pancreatic cancer. Int J Radiat Oncol Biol Phys 48:1081–1087PubMedCrossRefGoogle Scholar
  16. 16.
    Sindelar WF, Kinsella TJ (1999) Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol 10Suppl 4:226–230PubMedCrossRefGoogle Scholar
  17. 17.
    Kalser MH, Ellenberg SS (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899–903PubMedGoogle Scholar
  18. 18.
    Gastrointestinal Tumor Study Group (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59:2006–2010CrossRefGoogle Scholar
  19. 19.
    Bakkevold KE, Arnesjo B, Dahl O, Kambestad B (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater — results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A:698–703PubMedCrossRefGoogle Scholar
  20. 20.
    Demeure MJ, Doffek KM, Komorowski RA, Redlich PN, Zhu YR, Erickson BA, et al (1998) Molecular metastases in stage I pancreatic cancer: improved survival with adjuvant chemoradiation. Surgery 124:663–669PubMedCrossRefGoogle Scholar
  21. 21.
    Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776–782; discussion 782–774PubMedCrossRefGoogle Scholar
  22. 22.
    Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J, et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710PubMedCrossRefGoogle Scholar
  23. 23.
    Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576–1585PubMedCrossRefGoogle Scholar
  24. 24.
    Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210PubMedCrossRefGoogle Scholar
  25. 25.
    Neuhaus P, Oettle H, Post S, Gellert K, Ridwelski K, Schramm H, et al (2005) A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. Meeting of the American Society of Clinical Oncology, Orlando, May 14–17, 2005; Abstract 4013Google Scholar
  26. 26.
    Picozzi VJ, Kozarek RA, Traverso LW (2003) Interferonbased adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185:476–480PubMedCrossRefGoogle Scholar
  27. 27.
    Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, et al (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8:123–132PubMedCrossRefGoogle Scholar
  28. 28.
    Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, et al (2002) Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 20:2537–2544PubMedCrossRefGoogle Scholar
  29. 29.
    Spitz FR, Abbruzzese JL, Lee JE, Pisters PW, Lowy AM, Fenoglio CJ, et al (1997) Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15:928–937PubMedGoogle Scholar
  30. 30.
    Wolff R, Evans D, Crane C, Cleary K, Lenzi R, Abbruzzese J, et al (2002) Initial results of preoperative gemcitabine (GEM)-based chemoradiation for resectable pancreatic adenocarcinoma. Presented at the ASCO Annual Meeting, May 18–21, 2002, Orlando, Florida. Abstract 549Google Scholar
  31. 31.
    Raut CP, Grau AM, Staerkel GA, Kaw M, Tamm EP, Wolff RA, et al (2003) Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 7:118–126; discussion 127–118PubMedCrossRefGoogle Scholar
  32. 32.
    Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, et al (2000) Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 18:860–867PubMedGoogle Scholar
  33. 33.
    Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB III (1998) Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 16:317–323PubMedGoogle Scholar
  34. 34.
    Varadhachary GR, Evans DE, Crane C, Xiong HQ, Tamm HP, Lee JE, et al (2006) Initial results of preoperative gemcitabine (GEM) plus cisplatin followed by rapid fractionation chemoradiation for resectable pancreatic adenocarcinoma. American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, San Francisco, January 26–28, 2006. Abstract 247Google Scholar
  35. 35.
    Varadhachary GR, Tamm EP, Crane C, Evans DB, Wolff RA (2005) Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol 8:377–384PubMedCrossRefGoogle Scholar
  36. 36.
    Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, et al (2000) Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936–1948PubMedGoogle Scholar
  37. 37.
    Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ (2000) Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89:74–82PubMedCrossRefGoogle Scholar
  38. 38.
    Xiong HQ, Abbruzzese JL (2002) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29:31–37PubMedGoogle Scholar
  39. 39.
    Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11–31PubMedCrossRefGoogle Scholar
  40. 40.
    Grunwald V, Hidalgo M (2003) Development of the epidermal growth factor receptor inhibitor OSI-774. Semin Oncol 30:23–31PubMedCrossRefGoogle Scholar
  41. 41.
    Moore MJ, Goldstein J, Hamm J, Figer A, Hecht J, Gallinger S, Au H, et al (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 23(Suppl 16): A–1, 1sGoogle Scholar
  42. 42.
    Moore MJ (2005) Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin Oncol 32:5–6PubMedCrossRefGoogle Scholar
  43. 43.
    Iannitti D, Dipetrillo T, Akerman P, Barnett JM, Maia-Acuna C, Cruff D, et al (2005) Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28:570–575PubMedCrossRefGoogle Scholar
  44. 44.
    Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMedCrossRefGoogle Scholar
  45. 45.
    Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147PubMedCrossRefGoogle Scholar
  46. 46.
    Jaffee EM, Hruban RH, Canto M, Kern SE (2002) Focus on pancreas cancer. Cancer Cell 2:25–28PubMedCrossRefGoogle Scholar
  47. 47.
    Greten TF, Jaffee EM (1999) Cancer vaccines. J Clin Oncol 17:1047–1060PubMedGoogle Scholar
  48. 48.
    Laheru D, Jaffee EM (2005) Immunotherapy for pancreatic cancer — science driving clinical progress. Nat Rev Cancer 5:459–467PubMedCrossRefGoogle Scholar
  49. 49.
    Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, et al (2001) Novel allogenic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19:145–156PubMedGoogle Scholar
  50. 50.
    Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Soreide O, et al (1995) Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346:1399–1400PubMedCrossRefGoogle Scholar
  51. 51.
    Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, et al (2001) Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441–450PubMedCrossRefGoogle Scholar
  52. 52.
    Marshall J (2003) Carcinoembryonic antigen-based vaccines. Semin Oncol 30:30–36PubMedCrossRefGoogle Scholar
  53. 53.
    Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, et al (2005) Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccini-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23:720–731PubMedCrossRefGoogle Scholar
  54. 54.
    Abrams RA, Grochow LB, Chakravarthy A, Sohn TA, Zahurak ML, Haulk TL, Ord S, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL, Yeo CJ (1999) Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 44:1039–1046PubMedCrossRefGoogle Scholar
  55. 55.
    Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95:1685–1695PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • G. R. Varadhachary
    • 1
  • J. L. Abbruzzese
    • 2
  1. 1.Department of Gastrointestinal Medical Oncology Unit 426The University of Texas M.D. Anderson Cancer CenterHoustonUSA
  2. 2.Anderson Cancer CenterThe University of TexasHoustonUSA

Personalised recommendations